Viral Conjunctivitis-Pipeline Review, H1 2016

Viral Conjunctivitis-Pipeline Review, H1 2016

  • Products Id :- GMDHC7797IDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Viral Conjunctivitis-Pipeline Review, H1 2016', provides an overview of the Viral Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis

The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects

The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Viral Conjunctivitis Overview 6

Therapeutics Development 7

Pipeline Products for Viral Conjunctivitis-Overview 7

Viral Conjunctivitis-Therapeutics under Development by Companies 8

Viral Conjunctivitis-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Viral Conjunctivitis-Products under Development by Companies 11

Viral Conjunctivitis-Companies Involved in Therapeutics Development 12

Adenovir Pharma AB 12

NanoViricides, Inc. 13

Panoptes Pharma Ges.m.b.H. 14

Shire Plc 15

Starpharma Holdings Limited 16

Viral Conjunctivitis-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 25

APD-209-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

astodrimer-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

EKCCide-I-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

PP-001-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SHP-640-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

trisialic acid second generation-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Viral Conjunctivitis-Recent Pipeline Updates 33

Viral Conjunctivitis-Dormant Projects 37

Viral Conjunctivitis-Discontinued Products 38

Viral Conjunctivitis-Product Development Milestones 39

Featured News & Press Releases 39

May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment 39

Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis 39

Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis 40

May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model 40

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Figures

Number of Products under Development for Viral Conjunctivitis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Assessment by Monotherapy Products, H1 2016 17

Number of Products by Targets, H1 2016 18

Number of Products by Stage and Targets, H1 2016 18

Number of Products by Mechanism of Actions, H1 2016 20

Number of Products by Stage and Mechanism of Actions, H1 2016 20

Number of Products by Routes of Administration, H1 2016 22

Number of Products by Stage and Routes of Administration, H1 2016 22

Number of Products by Stage and Molecule Types, H1 2016 24

List of Tables

Number of Products under Development for Viral Conjunctivitis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 9

Comparative Analysis by Early Stage Development, H1 2016 10

Products under Development by Companies, H1 2016 11

Viral Conjunctivitis-Pipeline by Adenovir Pharma AB, H1 2016 12

Viral Conjunctivitis-Pipeline by NanoViricides, Inc., H1 2016 13

Viral Conjunctivitis-Pipeline by Panoptes Pharma Ges.m.b.H., H1 2016 14

Viral Conjunctivitis-Pipeline by Shire Plc, H1 2016 15

Viral Conjunctivitis-Pipeline by Starpharma Holdings Limited, H1 2016 16

Assessment by Monotherapy Products, H1 2016 17

Number of Products by Stage and Target, H1 2016 19

Number of Products by Stage and Mechanism of Action, H1 2016 21

Number of Products by Stage and Route of Administration, H1 2016 23

Number of Products by Stage and Molecule Type, H1 2016 24

Viral Conjunctivitis Therapeutics-Recent Pipeline Updates, H1 2016 33

Viral Conjunctivitis-Dormant Projects, H1 2016 37

Viral Conjunctivitis-Discontinued Products, H1 2016 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Adenovir Pharma AB

NanoViricides, Inc.

Panoptes Pharma Ges.m.b.H.

Shire Plc

Starpharma Holdings Limited

Viral Conjunctivitis Therapeutic Products under Development, Key Players in Viral Conjunctivitis Therapeutics, Viral Conjunctivitis Pipeline Overview, Viral Conjunctivitis Pipeline, Viral Conjunctivitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 147360
Site License
USD 4000 INR 294720
Corporate User License
USD 6000 INR 442080



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]